{
    "clinical_study": {
        "@rank": "14969", 
        "acronym": "SAMCIS", 
        "arm_group": [
            {
                "arm_group_label": "MSC infusion", 
                "arm_group_type": "Active Comparator", 
                "description": "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset"
            }, 
            {
                "arm_group_label": "SHAM infusion", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Infusion of normal saline placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine if mesenchymal stem cells given by IV is feasible\n      and safe in patients with recent ischemic stroke and to decide the maximum tolerated dose\n      when given between 3-10 days after an ischemic stroke."
        }, 
        "brief_title": "Mesenchymal Stromal Cells for Ischemic Stroke", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Ischemic Stroke", 
        "condition_browse": {
            "mesh_term": [
                "Ischemia", 
                "Stroke", 
                "Cerebral Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a randomized, double-blind, placebo controlled study. . Approximately 48 subjects\n      will be enrolled in the trial, undergo a real or SHAM MSC IV infusion and will be follow out\n      to 1 year. There will potentially be 4 Cohorts with the dose escalation at a 3:1\n      randomization schedule\n\n      Objectives:\n\n        -  The primary hypothesis' are that intravenous administration of allogeneic bone marrow\n           derived mesenchymal stem cells is feasible and safe in patients with recent ischemic\n           stroke and to determine the maximum tolerated dose (MTD) of IV MSCs when administered\n           sub-acutely between 3-10 days following ischemic stroke.\n\n        -  The secondary hypothesis is that allogeneic MSC transplantation will improve functional\n           outcome after recent ischemic stroke.\n\n      Safety and clinical efficacy points to be evaluated at Day 7 clinic visit, Day 30, Day 60,\n      Day 90, and Day 180.  Primary outcome or Primary endpoint of the study is to define the\n      safety or harm of the MSCs"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. acute ischemic stroke\n\n          2. age 18 to 83 years\n\n          3. post stroke mRS > 3\n\n          4. NIHSS of 7-25\n\n          5. Deficits on the total NIHSS can be lower than 7 provided the patients have moderate\n             aphasia or visual loss (2 on the Best Language or Visual loss NIHSS subcomponent)\n             *Criteria for mRS not used for this category of subjects\n\n          6. Last seen normal st within 3-9 days prior to stroke.  Time of onset for wake-up\n             stroke will be defined as the time the patient woke up with symptoms.\n\n          7. stem cell transplantation procedure must be performed between 3-10 days after stroke\n             symptom onset\n\n        Exclusion Criteria:\n\n          1. Ischemic stroke, primary hemorrhagic or traumatic lesion of the brain or myocardial\n             infarction within past 30 days prior to current stroke.\n\n          2. Mechanical heart valve\n\n          3. Uncontrolled seizure disorder, defined as a seizure within the last 6 months\n\n          4. Developmental delay\n\n          5. Chronic kidney disease\n\n          6. Hepatic disease or altered liver function\n\n          7. Pulmonary disease\n\n          8. Cancer within 5 years prior to study\n\n          9. Prior immunosuppression, including  chemotherapy within last 3 years\n\n         10. Known HIV\n\n         11. Uncorrected coagulopathy or severe anemia\n\n         12. Pregnancy\n\n         13. Unable to undergo MRI or CT scan\n\n         14. Imaging shows clinically significant hemorrhage"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "83 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922908", 
            "org_study_id": "SAMCIS"
        }, 
        "intervention": [
            {
                "arm_group_label": "MSC infusion", 
                "description": "Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset", 
                "intervention_name": "MSC Infusion", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "SHAM infusion", 
                "description": "Normal saline", 
                "intervention_name": "Placebo Comparator", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Ischemic", 
            "Stroke", 
            "Stem Cells", 
            "MSC", 
            "Allogeneic", 
            "Bone Marrow"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": {
            "contact": {
                "last_name": "Sean Savitz, MD"
            }, 
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77030"
                }, 
                "name": "University of Texas HealthScience Center- Houston"
            }, 
            "investigator": {
                "last_name": "Sean Savitz, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "SAfety of Mesenchymal Stromal Cells for Ischemic Stroke", 
        "overall_contact": {
            "email": "farhaan.vahidy@uth.tmc.edu", 
            "last_name": "Farhaan S Vahidy, MD, MPH"
        }, 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center, Houston", 
            "last_name": "Sean Savitz, md", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "maximum tolerated dose (MTD) of IV MSCs", 
            "safety_issue": "Yes", 
            "time_frame": "24 hours"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922908"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center, Houston", 
            "investigator_full_name": "Sean Savitz", 
            "investigator_title": "Professor, Department of Neurology, Director, Stroke Program", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": {
            "description": "as assessed by changes in mRS, NIHSS, Fugyl-Meyer and Barthel Index", 
            "measure": "Improved functional outcome", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "source": "The University of Texas Health Science Center, Houston", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sean Savitz", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}